Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 7, 2006 - Issue 16
Submit an article Journal homepage
140
Views
24
CrossRef citations to date
0
Altmetric
Review

Point mutations of protein kinases and individualised cancer therapy

Michael Davies Fellow, University of Texas – M D Anderson Cancer Center, Department of Medical Oncology, 1515 Holcombe Blvd, Unit 10, Houston, TX 77030, USA. [email protected]
,
Bryan Hennessy Assistant Professor, Gynecologic Medical Oncology, University of Texas – M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 10, Houston, TX 77030, USA
&
Gordon B Mills Professor, Chairman, University of Texas – M. D. Anderson Cancer Center, Department of Molecular Therapeutics, 151 Holcombe Blvd, Unit 950, Houston, TX 77030, USA
Pages 2243-2261 | Published online: 24 Oct 2006

Bibliography

  • COLVIN OM, FRIEDMAN HS: Alkylating agents. In Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA. (Ed.). Lippincott, Williams and Wilkins, New York, US (2005):332-344.
  • FARBER S, DIAMOND LK, MERCER RD, AL E: Temporary remissions in acute leukemias in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. (1948) 238:787-793.
  • ROUS P: Sarcoma of the fowl transmissible by an agent separable from the tumor cells. J.Exp. Med. (1911) 13:397-411.
  • HOWLEY PM, GANEM D, KIEFF E: DNA viruses. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Ed.). Lippincott, Williams, and Wilkins, New York, US (2005):173-184.
  • HUEBNER RJ, TODARO GJ: Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci. USA (1969) 64(3):1087-1094.
  • BRUGGE JS, ERIKSON RL: Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature (1977) 269(5626):346-348.
  • MARTIN GS: The road to Src. Oncogene (2004) 23:7910-7917.
  • SHALLOWAY D, ZELENETZ AD, COOPER GM: Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. Cell (1981) 24(2):531-541.
  • SJOBLOM T, JONES S, WOOD LD et al.: The consensus coding sequences of human breast and colorectal cancers. Science (2006):1133427.
  • LEVINSON AD, OPPERMANN H, LEVINTOW L, VARMUS HE, BISHOP JM: Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell (1978) 15(2):561-572.
  • KHARAS MG, FRUMAN DA: Abl oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. (2005) 65(6):2047-2053.
  • STEELMAN LS, POHNERT SC, SHELTON JG et al.: Jak/STAT, Raf/MEK/ERK, PI3K/Akt and Bcr-Abl in cell cycle progression and leukemogenesis. Leukemia (2004) 18(2):189-218.
  • ZOU X, CALAME K: Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. (1999) 274(26):18141-18144.
  • HENNESSY BT, SMITH DL, RAM PT, LU Y, MILLS GB: Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat. Rev. Drug Discov. (2005) 4(12):988-1004.
  • DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2(5):561-566.
  • DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
  • O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with IFN and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
  • GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science (2001) 293(5531):876-880.
  • SHAH NP, NICOLL JM, NAGAR B et al.: Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic-phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125.
  • O'HARE T, WALTERS DK, STOFFREGEN EP et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. (2005) 65(11):4500-4505.
  • SCHEINFELD N: A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J. Drugs Dermatol. (2006) 5(2):117-122.
  • DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347(7):472-480.
  • COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348(13):1201-1214.
  • DE MESTIER P, DES GUETZ G: Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J. Surg. (2005) 29(3):357-361; discussion 362.
  • SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER2/Neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
  • PRESS M, BERNSTEIN L, THOMAS P et al.: HER2/Neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. (1997) 15(8):2894-2904.
  • BRAND FX, RAVANEL N, GAUCHEZ AS et al.: Prospect for anti-HER2 receptor therapy in breast cancer. Anticancer Res. (2006) 26(1B):715-722.
  • BASELGA J, NORTON L, ALBANELL J, KIM YM, MENDELSOHN J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/Neu overexpressing human breast cancer xenografts. Cancer Res. (1998) 58(13):2825-2831.
  • SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a mAb against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
  • MASS RD, PRESS MF, ANDERSON S et al.: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer (2005) 6(3):240-246.
  • ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
  • PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
  • VAN DER ZWAN SM, DEMATTEO RP: Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 104(9):1781-1788.
  • DEMATTEO RP, LEWIS JJ, LEUNG D et al.: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. (2000) 231(1):51-58.
  • NG EH, POLLOCK RE, MUNSELL MF, ATKINSON EN, ROMSDAHL MM: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. (1992) 215(1):68-77.
  • HIROTA S, ISOZAKI K: Pathology of gastrointestinal stromal tumors. Pathol. Int. (2006) 56(1):1-9.
  • FLETCHER CD, BERMAN JJ, CORLESS C et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int. J. Surg. Pathol. (2002) 10(2):81-89.
  • LONGLEY BJ, TYRRELL L, LU S-Z et al.: Somatic c-Kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. (1996) 12(3):312-314.
  • HIROTA S, ISOZAKI K, MORIYAMA Y et al.: Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science (1998) 279(5350):577-580.
  • SOMMER G, AGOSTI V, EHLERS I et al.: Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. USA (2003) 100(11):6706-6711.
  • RUBIN BP, SINGER S, TSAO C et al.: Kit activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. (2001) 61(22):8118-8121.
  • HEINRICH MC, CORLESS CL, DUENSING A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299(5607):708-710.
  • HIROTA S, OHASHI A, NISHIDA T et al.: Gain-of-function mutations of platelet-derived growth factor receptor-α gene in gastrointestinal stromal tumors. Gastroenterology (2003) 125(3):660-667.
  • SAVAGE DG, ANTMAN KH: Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med. (2002) 346(9):683-693.
  • TUVESON DA, WILLIS NA, JACKS T et al.: STI571 inactivation of the gastrointestinal stromal tumor c-Kit oncoprotein: biological and clinical implications. Oncogene (2001) 20(36):5054-5058.
  • JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344(14):1052-1056.
  • HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21(23):4342-4349.
  • WARDELMANN E, THOMAS N, MERKELBACH-BRUSE S et al.: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple Kit mutations. Lancet Oncol (2005) 6(4):249-251.
  • TAMBORINI E, GABANTI E, LAGONIGRO MS et al.: Kit/Val654 Ala receptor detected in one imatinib-resistant GIST patient. Cancer Res. (2005) 65(3):1115; author reply 1115.
  • YAMAGUCHI M, MATSUMOTO T, TATE G, HIGUCHI T: Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-Kit protooncogene. J. Gastroenterol. (2004) 39(9):904-905.
  • CHEN LL, TRENT JC, WU EF et al.: A missense mutation in Kit kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. (2004) 64(17):5913-5919.
  • TAMBORINI E, BONADIMAN L, GRECO A et al.: A new mutation in the Kit ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 127(1):294-299.
  • ANTONESCU CR, BESMER P, GUO T et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. (2005) 11(11):4182-4190.
  • PRENEN H, COOLS J, MENTENS N et al.: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. (2006) 12(8):2622-2627.
  • DEBIEC-RYCHTER M, COOLS J, DUMEZ H et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 128(2):270-279.
  • PARKIN DM, BRAY F, FERLAY J, PISANI P: Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55(2):74-108.
  • KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the EGFR tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama (2003) 290(16):2149-2158.
  • FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. (2003) 21(12):2237-2246.
  • SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
  • HERBST RS, PRAGER D, HERMANN R et al.: Tribute: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(25):5892-5899.
  • HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trialb – INTACT 2. J. Clin. Oncol. (2004) 22(5):785-794.
  • PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
  • LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the EGFR underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
  • PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101(36):13306-13311.
  • HUANG SF, LIU HP, LI LH et al.: High frequency of EGFR mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. (2004) 10(24):8195-8203.
  • KIM KS, JEONG JY, KIM YC et al.: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. (2005) 11(6):2244-2251.
  • TOKUMO M, TOYOOKA S, KIURA K et al.: The relationship between EGFR mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. (2005) 11(3):1167-1173.
  • JI H, LI D, CHEN L et al.: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 9(6):485-495.
  • POLITI K, ZAKOWSKI MF, FAN P-D et al.: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. (2006) 20(11):1496-1510.
  • SORDELLA R, BELL DW, HABER DA, SETTLEMAN J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 305(5687):1163-1167.
  • TRACY S, MUKOHARA T, HANSEN M et al.: Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. (2004) 64(20):7241-7244.
  • WEINSTEIN IB: Cancer: enhanced: addiction to oncogenes – the achilles heal of cancer. Science (2002) 297(5578):63-64.
  • TSAO M-S, SAKURADA A, CUTZ J-C et al.: Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. (2005) 353(2):133-144.
  • EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutations in the EGFR and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23(25):5900-5909.
  • KOBAYASHI S, BOGGON TJ, DAYARAM T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352(8):786-792.
  • PAO W, MILLER VA, POLITI KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 2(3):e73.
  • CAPPUZZO F, HIRSCH FR, ROSSI E et al.: EGFR gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. (2005) 97(9):643-655.
  • AMANN J, KALYANKRISHNA S, MASSION PP et al.: Aberrant EGFR signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. (2005) 65(1):226-235.
  • STEPHENS P, HUNTER C, BIGNELL G et al.: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 431(7008):525-526.
  • SHIGEMATSU H, TAKAHASHI T, NOMURA M et al.: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. (2005) 65(5):1642-1646.
  • COHEN EE, LINGEN MW, MARTIN LE et al.: Response of some head and neck cancers to EGFR tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res. (2005) 11(22):8105-8108.
  • HIRATA A, HOSOI F, MIYAGAWA M et al.: HER2 overexpression increases sensitivity to gefitinib, an EGFR tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. (2005) 65(10):4253-4260.
  • GIEHL K: Oncogenic Ras in tumour progression and metastasis. Biol. Chem. (2005) 386(3):193-205.
  • COLICELLI J: Human Ras superfamily proteins and related GTPases. Sci. STKE (2004) 2004(250):RE13.
  • GRADY WM, MARKOWITZ SD: Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum. Genet. (2002) 3:101-128.
  • GOEL VK, LAZAR AJ, WARNEKE CL, REDSTON MS, HALUSKA FG: Examination of mutations in b-Raf, n-Ras and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. (2006) 126(1):154-160.
  • GOYDOS JS, MANN B, KIM HJ et al.: Detection of b-Raf and N-Ras mutations in human melanoma. J. Am. Coll. Surg. (2005) 200(3):362-370.
  • SMALLEY KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer (2003) 104(5):527-532.
  • DAVIES H, BIGNELL GR, COX C et al.: Mutations of the b-Raf gene in human cancer. Nature (2002) 417(6892):949-954.
  • OMHOLT K, PLATZ A, KANTER L, RINGBORG U, HANSSON J: n-Ras and b-Raf mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. (2003) 9(17):6483-6488.
  • GORDEN A, OSMAN I, GAI W et al.: Analysis of b-Raf and n-Ras mutations in metastatic melanoma tissues. Cancer Res. (2003) 63(14):3955-3957.
  • CURTIN JA, FRIDLYAND J, KAGESHITA T et al.: Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. (2005) 353(20):2135-2147.
  • WONG CW, FAN YS, CHAN TL et al.: b-Raf and n-Ras mutations are uncommon in melanomas arising in diverse internal organs. J. Clin. Pathol. (2005) 58(6):640-644.
  • ZUIDERVAART W, VAN NIEUWPOORT F, STARK M et al.: Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of b-Raf or Ras. Br. J. Cancer (2005) 92(11):2032-2038.
  • RIMOLDI D, SALVI S, LIENARD D et al.: Lack of b-Raf mutations in uveal melanoma. Cancer Res. (2003) 63(18):5712-5715.
  • PATTON EE, WIDLUND HR, KUTOK JL et al.: b-Raf mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. (2005) 15(3):249-254.
  • POLLOCK PM, HARPER UL, HANSEN KS et al.: High frequency of b-Raf mutations in nevi. Nat. Genet. (2003) 33(1):19-20.
  • YAZDI AS, PALMEDO G, FLAIG MJ et al.: Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. (2003) 121(5):1160-1162.
  • TSAO H, GOEL V, WU H, YANG G, HALUSKA FG: Genetic interaction between n-Ras and b-Raf mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. (2004) 122(2):337-341.
  • HINGORANI SR, JACOBETZ MA, ROBERTSON GP, HERLYN M, TUVESON DA: Suppression of b-Raf (V599E) in human melanoma abrogates transformation. Cancer Res. (2003) 63(17):5198-5202.
  • STRUMBERG D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) (2005) 41(12):773-784.
  • AHMAD T, EISEN T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. (2004) 10(18 Pt 2):6388S-6392S.
  • AHMAD T, MARAIS R, PYLE L et al.: BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. 2004 ASCO Annual Meeting. New Orleans, LA, US (2004).
  • ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO Annual Meeting. Orlando, FL, US (2005).
  • YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
  • FLAHERTY KT, BROSE M, SCHUCHTER L et al.: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. ASCO Annual Meeting. New Orleans, LA, US (2004).
  • BACHMAN KE, ARGANI P, SAMUELS Y et al.: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. (2004) 3(8):772-775.
  • KANG S, BADER AG, VOGT PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA (2005) 102(3):802-807.
  • SAMUELS Y, WANG Z, BARDELLI A et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304(5670):554.
  • BADER AG, KANG S, VOGT PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. USA (2006) 103(5):1475-1479.
  • LI SY, RONG M, GRIEU F, IACOPETTA B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. (2006) 96(1):91-95.
  • CAMPBELL IG, RUSSELL SE, CHOONG DY et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. (2004) 64(21):7678-7681.
  • YEN-YING MA S-JW, YU-CHEN LIN, JIA-CHYI LUNG et al.: PIK3CA as an oncogene in cervical cancer. Oncogene (2000) 19(23):2739-2744.
  • WOENCKHAUS J, STEGER K, WERNER E et al.: Genomic gain of PIK3CA and increased expression of p110α are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. (2002) 198(3):335-342.
  • SHAYESTEH L, LU Y, KUO WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. (1999) 21(1):99-102.
  • MIZOGUCHI M, NUTT CL, MOHAPATRA G, LOUIS DN: Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. (2004) 14(4):372-377.
  • BRODERICK DK, DI C, PARRETT TJ et al.: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. (2004) 64(15):5048-5050.
  • JUCKER M, SUDEL K, HORN S et al.: Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia (2002) 16(5):894-901.
  • CRUL M, ROSING H, DE KLERK GJ et al.: Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur. J. Cancer (2002) 38(12):1615-1621.
  • VANHAESEBROECK B, ALI K, BILANCIO A, GEERING B, FOUKAS LC: Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. (2005) 30(4):194-204.
  • WARD SG, FINAN P: Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. (2003) 3(4):426-434.
  • IRIE HY, PEARLINE RV, GRUENEBERG D et al.: Distinct roles of Akt-1 and Akt-2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. (2005) 171(6):1023-1034.
  • YOELI-LERNER M, YIU GK, RABINOVITZ I et al.: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell (2005) 20(4):539-550.
  • HUTCHINSON JN, JIN J, CARDIFF RD, WOODGETT JR, MULLER WJ: Activation of Akt-1 (PKB-{α}) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. (2004) 64(9):3171-3178.
  • LAW BK: Rapamycin: an anti-cancer immunosuppressant? Crit. Rev. Oncol. Hematol. (2005) 56(1):47-60.
  • GEORGAKIS GV, YOUNES A: From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther. (2006) 6(1):131-140.
  • O'REILLY KE, ROJO F, SHE QB et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. (2006) 66(3):1500-1508.
  • WITZIG TE, GEYER SM, GHOBRIAL I et al.: Phase II Trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. (2005) 23(23):5347-5356.
  • MROZEK K, HEEREMA NA, BLOOMFIELD CD: Cytogenetics in acute leukemia. Blood Rev. (2004) 18(2):115-136.
  • BENNETT JM, CATOVSKY D, DANIEL MT, AL E: Proposals for the classification of the acute leukaemias: French–American–British Cooperative Group. Br. J. Haematol. (1976) 33:451-458.
  • WHEATLEY K, BURNETT AK, GOLDSTONE AH et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. UK Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br. J. Haematol. (1999) 107(1):69-79.
  • REILLY JT: Flt-3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk. Lymphoma (2003) 44(1):1-7.
  • DREXLER HG: Expression of Flt-3 receptor and response to Flt-3 ligand by leukemic cells. Leukemia (1996) 10(4):588-599.
  • CAROW CE, LEVENSTEIN M, KAUFMANN SH et al.: Expression of the hematopoietic growth factor receptor Flt-3 (STK-1/Flk2) in human leukemias. Blood (1996) 87(3):1089-1096.
  • HAWLEY TS, FONG AZ, GRIESSER H, LYMAN SD, HAWLEY RG: Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing Flt-3 ligand. Blood (1998) 92(6):2003-2011.
  • NAKAO M, YOKOTA S, IWAI T et al.: Internal tandem duplication of the Flt-3 gene found in acute myeloid leukemia. Leukemia (1996) 10(12):1911-1918.
  • THIEDE C, STEUDEL C, MOHR B et al.: Analysis of Flt-3-activating mutations in 979 patients with acute myelogenous leukemia: association with Fab subtypes and identification of subgroups with poor prognosis. Blood (2002) 99(12):4326-4335.
  • XU F, TAKI T, YANG HW et al.: Tandem duplication of the Flt-3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. (1999) 105(1):155-162.
  • SHIH LY, LIN TL, WANG PN et al.: Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer (2004) 101(5):989-998.
  • GEORGIOU G, KARALI V, ZOUVELOU C et al.: Serial determination of Flt-3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br. J. Haematol. (2006) 134(3):302-306.
  • KIYOI H, YANADA M, OZEKIA K: Clinical significance of Flt-3 in leukemia. Int. J. Hematol. (2005) 82(2):85-92.
  • KIYOI H, NAOE T, NAKANO Y et al.: Prognostic implication of Flt-3 and n-Ras gene mutations in acute myeloid leukemia. Blood (1999) 93(9):3074-3080.
  • ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: Flt-3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. (2000) 111(1):190-195.
  • KIYOI H, NAOE T: Flt-3 mutations in acute myeloid leukemia. Methods Mol. Med. (2006) 125:189-197.
  • KONDO M, HORIBE K, TAKAHASHI Y et al.: Prognostic value of internal tandem duplication of the Flt-3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol. (1999) 33(6):525-529.
  • KIYOI H, TOWATARI M, YOKOTA S et al.: Internal tandem duplication of the Flt-3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 12(9):1333-1337.
  • GRIFFITH J, BLACK J, FAERMAN C et al.: The structural basis for autoinhibition of Flt-3 by the juxtamembrane domain. Mol. Cell (2004) 13(2):169-178.
  • MIZUKI M, FENSKI R, HALFTER H et al.: Flt-3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood (2000) 96(12):3907-3914.
  • BIRKENKAMP KU, GEUGIEN M, LEMMINK HH, KRUIJER W, VELLENGA E: Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia (2001) 15(12):1923-1931.
  • FENSKI R, FLESCH K, SERVE S et al.: Constitutive activation of Flt-3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. (2000) 108(2):322-330.
  • YAMAMOTO Y, KIYOI H, NAKANO Y et al.: Activating mutation of D835 within the activation loop of Flt-3 in human hematologic malignancies. Blood (2001) 97(8):2434-2439.
  • ABU-DUHIER FM, GOODEVE AC, WILSON GA et al.: Identification of novel Flt-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematology (2001) 113(4):983-988.
  • NOMDEDEU JF, BRUNET S, COLOMER D et al.: D835 mutations are commonly associated with other molecular lesions in adult AML. Blood (2001) 98:579a.
  • SCHMIDT-ARRAS D, SCHWABLE J, BOHMER FD, SERVE H: Flt-3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des (2004) 10(16):1867-1883.
  • KIYOI H, NAOE T: Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with Flt-3 mutation. Int. J. Hematol. (2006) 83(4):301-308.
  • O'FARRELL A-M, FORAN JM, FIEDLER W et al.: An innovative Phase I clinical study demonstrates inhibition of Flt-3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. (2003) 9(15):5465-5476.
  • GOLUB TR, BARKER GF, LOVETT M, GILLILAND DG: Fusion of PDGF receptor β to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77(2):307-316.
  • BARTRAM C R, DE KLEIN A, HAGEMEIJER A et al.: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1983) 306(5940):277-280.
  • PERCY MJ, MCMULLIN MF: The V617F Jak-2 mutation and the myeloproliferative disorders. Hematol. Oncol. (2005) 23(3-4):91-93.
  • VALENTINO L, PIERRE J: Jak/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem. Pharmacol. (2006) 71(6):713-721.
  • UGO V, MARZAC C, TEYSSANDIER I et al.: Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp. Hematol. (2004) 32(2):179-187.
  • KRALOVICS R, GUAN Y, PRCHAL JT: Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. (2002) 30(3):229-236.
  • KRALOVICS R, PASSAMONTI F, BUSER AS et al.: A gain-of-function mutation of Jak-2 in myeloproliferative disorders. N. Engl. J. Med. (2005) 352(17):1779-1790.
  • JAMES C, UGO V, LE COUEDIC J-P et al.: A unique clonal Jak-2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 434(7037):1144-1148.
  • BAXTER EJ, SCOTT LM, CAMPBELL PJ et al.: Acquired mutation of the tyrosine kinase Jak-2 in human myeloproliferative disorders. The Lancet (2005) 365(9464):1054-1061.
  • LEVINE RL, WADLEIGH M, COOLS J et al.: Activating mutation in the tyrosine kinase Jak-2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 7(4):387-397.
  • JONES AV, KREIL S, ZOI K et al.: Widespread occurrence of the Jak-2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 106(6):2162-2168.
  • CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
  • MORONI M, VERONESE S, BENVENUTI S et al.: Gene copy number for EGFR and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. The Lancet Oncology (2005) 6(5):279-286.
  • LIEVRE A, BACHET J-B, LE CORRE D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66(8):3992-3995.
  • LEBEDEVA IV, SARKAR D, SU ZZ et al.: Molecular target-based therapy of pancreatic cancer. Cancer Res. (2006) 66(4):2403-2413.
  • ITTMANN MM: Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol. Rep. (1998) 5(6):1329-1335.
  • MAEHAMA T, DIXON JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. (1998) 273(22):13375-13378.
  • STAMBOLIC V, SUZUKI A, DE LA POMPA JL et al.: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 95(1):29-39.
  • TASHIRO H, BLAZES MS, WU R et al.: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. (1997) 57(18):3935-3940.
  • RISINGER JI, HAYES AK, BERCHUCK A, BARRETT JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. (1997) 57(21):4736-4738.
  • MAXWELL GL, RISINGER JI, GUMBS C et al.: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. (1998) 58(12):2500-2503.
  • TENG DH, HU R, LIN H et al.: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. (1997) 57(23):5221-5225.
  • PERREN A, WENG LP, BOAG AH et al.: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. (1999) 155(4):1253-1260.
  • BIRCK A, AHRENKIEL V, ZEUTHEN J, HOU-JENSEN K, GULDBERG P: Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Invest. Dermatol. (2000) 114(2):277-280.
  • TSAO H, ZHANG X, BENOIT E, HALUSKA FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene (1998) 16(26):3397-3402.
  • GULDBERG P, THOR STRATEN P, BIRCK A et al.: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. (1997) 57(17):3660-3663.
  • HALACHMI N, HALACHMI S, EVRON E et al.: Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer (1998) 23(3):239-243.
  • PARSONS DW, WANG TL, SAMUELS Y et al.: Colorectal cancer: mutations in a signalling pathway. Nature (2005) 436(7052):792.
  • DAVIES H, HUNTER C, SMITH R et al.: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. (2005) 65(17):7591-7595.
  • STEPHENS P, EDKINS S, DAVIES H et al.: A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. (2005) 37(6):590-592.
  • WANG Z, SHEN D, PARSONS DW et al.: Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 304(5674):1164-1166.
  • BARDELLI A, PARSONS DW, SILLIMAN N et al.: Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 300(5621):949.
  • LIOTTA LA, ESPINA V, MEHTA AI et al.: Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 3(4):317-325.
  • BASELGA J: Targeting tyrosine kinases in cancer: the second wave. Science (2006) 312(5777):1175-1178.
  • RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
  • SACHSE C, ECHEVERRI CJ: Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene (2005) 23(51):8384-8391.
  • KAELIN WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer (2005) 5(9):689-698.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.